Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Authors:
Open Access
- 9 November 2021
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 20 (1) , 1-10
Abstract
Background: Recent studies indicated that sodium glucose cotransporter (SGLT)2 inhibition increases levels of ketone bodies in the blood in patients with type 1 and 2 diabetes. Other studies suggested that in patients with chronic heart failure (CHF), increased myocardial oxygen demand can be provided by ketone bodies as a fuel substrate. Experimental studies reported that ketone bodies, specifically beta-hydroxybutyrate (β-OHB) may increase blood pressure (BP) by impairing endothelium-dependant relaxation, thereby leading to increased vascular stiffness. In our study we assessed whether the SGLT 2 inhibition with empagliflozin increases ketone bodies in patients with stable CHF and whether such an increase impairs BP and vascular function. Methods: In a prospective, double blind, placebo controlled, parallel-group single centre study 75 patients with CHF (left ventricular ejection fraction 39.0 ± 8.2%) were randomised (2:1) to the SGLT-2 inhibitor empagliflozin 10 mg orally once daily or to placebo, 72 patients completed the study. After a run-in phase we evaluated at baseline BP by 24 h ambulatory blood pressure (ABP) monitoring, vascular stiffness parameters by the SphygmoCor system (AtCor Medical, Sydney, NSW, Australia) and fasting metabolic parameters, including β-OHB by an enzymatic assay (Beckman Coulter DxC 700 AU). The same measurements were repeated 12 weeks after treatment. In 19 of the 72 patients serum levels of β-OHB were beneath the lower border of our assay (< 0.05 mmol/l) therefore being excluded from the subsequent analysis. Results: In patients with stable CHF, treatment with empagliflozin (n = 36) was followed by an increase of β-OHB by 33.39% (p = 0.017), reduction in 24 h systolic (p = 0.038) and diastolic (p = 0.085) ABP, weight loss (p = 0.003) and decrease of central systolic BP (p = 0.008) and central pulse pressure (p = 0.008). The increase in β-OHB was related to an attenuated decrease of empagliflozin-induced 24 h systolic (r = 0.321, p = 0.069) and diastolic (r = 0.516, p = 0.002) ABP and less reduction of central systolic BP (r = 0.470, p = 0.009) and central pulse pressure (r = 0.391, p = 0.033). No significant changes were seen in any of these parameters after 12 weeks of treatment in the placebo group (n = 17). Conclusion: In patients with stable CHF ketone bodies as assessed by β-OHB increased after treatment with empagliflozin. This increase led to an attenuation of the beneficial effects of empagliflozin on BP and vascular parameters. Trial registration The study was registered at http://www.clinicaltrials.gov (NCT03128528).Keywords
Funding Information
- Boehringer Ingelheim
- Universitätsklinikum Erlangen
This publication has 30 references indexed in Scilit:
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” HypothesisDiabetes Care, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- The Failing Heart Relies on Ketone Bodies as a FuelCirculation, 2016
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 DiabetesDiabetes, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- The impact of the ketogenic diet on arterial morphology and endothelial function in children and young adults with epilepsy: A case–control studySeizure: European Journal of Epilepsy, 2014
- Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysisEuropean Heart Journal, 2010
- Expert consensus document on arterial stiffness: methodological issues and clinical applicationsEuropean Heart Journal, 2006
- Hyperketonemia (ketosis), oxidative stress and type 1 diabetesPathophysiology, 2006
- Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure WaveformHypertension, 2001